

Publications 2010-2012

Title	Authors	Journal
Late-onset Bloodstream Infections in Preterm infants: a Two-Year Survey	Grisaru-Soen G, Friedman T, Dollberg S, Mishali H, Carmeli Y.	Pediatr Int. 2012 Jun 6.
Asymptomatic rectal carriage of bla(KPC) producing carbapenem-resistant Enterobacteriaceae: who is prone to become clinically infected?	Schechner V, Kotlovsky T, Kazma M, Mishali H, Schwartz D, Navon-Venezia S, Schwaber MJ, Carmeli Y.	Clin Microbiol Infect. 2012 Apr 6.
Carriage of methicillin-resistant Staphylococcus aureus on admission to European rehabilitation centres--a prospective study	Bilavsky E, Lerman Y, Rabinovich A, Salomon J, Lawrence C, Rossini A, Salvia A, Samsó JV, Fierro J, Hochman M, Kazma M, Klein A, Schwaber MJ, Carmeli Y ; MOSAR WP5 study team.	Clin Microbiol Infect. 2012 Jun;18(6):E164-9.
Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria	Akova M, Daikos GL, Tzouveleakis L, Carmeli Y.	Clin Microbiol Infect. 2012 May;18(5):439-48.
Identification and screening of carbapenemase-producing Enterobacteriaceae	Nordmann P, Gniadkowski M, Giske CG, Poirel L, Woodford N, Miriagou V; European Network on Carbapenemases	Clin Microbiol Infect. 2012 May;18(5):432-8.
Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe	Cantón R, Akóva M, Carmeli Y , Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Miriagou V, Naas T, Rossolini GM, Samuelsen Ø, Seifert H, Woodford N, Nordmann P; European Network on Carbapenemases	Clin Microbiol Infect. 2012 May;18(5):413-31.
Reduced susceptibility to chlorhexidine among extremely-drug-resistant strains of Klebsiella pneumoniae	Naparstek L, Carmeli Y , Chmelnitsky I, Banin E, Navon-Venezia S.	J Hosp Infect. 2012 May;81(1):15-9
Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum- β -lactamase-producing Enterobacteriaceae	Collins VL, Marchaim D, Pogue JM, Moshos J, Bheemreddy S, Sunkara B, Shallal A, Chugh N, Eiseler S, Bhargava P, Blunden C, Lephart PR, Memon BI, Hayakawa K, Abreu-Lanfranco O, Chopra T, Munoz-Price LS, Carmeli Y , Kaye KS.	Antimicrob Agents Chemother. 2012 Apr;56(4):2173-7
Introduction of OXA-48-producing Enterobacteriaceae to Israeli hospitals by medical tourism	Adler A, Shklyar M, Schwaber MJ, Navon-Venezia S, Dhaher Y, Edgar R, Solter E, Benenson S, Masarwa S, Carmeli Y.	J Antimicrob Chemother. 2011 Dec;66(12):2763-6.
Dissemination of the Klebsiella pneumoniae carbapenemase in the health care settings: tracking the trails of an elusive offender	Adler A, Carmeli Y.	MBio. 2011 Dec 20;2(6).
Culture-based detection of methicillin-resistant Staphylococcus aureus by a network of European laboratories: an	Gazin M, Lee A, Derde L, Kazma M, Lammens C, Ieven M, Bonten M, Carmeli Y , Harbarth S, Brun-Buisson	Eur J Clin Microbiol Infect Dis. 2011 Dec

external quality assessment study	C, Goossens H, Malhotra-Kumar S; on behalf of the MOSAR WP2 Study Team	11
Laboratory evaluation of the ESwab transport system for the recovery of carbapenem-resistant <i>Acinetobacter baumannii</i>	Moran-Gilad J, Schwartz D, Navon-Venezia S, Carmeli Y .	Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1429-33.
Carbapenem stewardship: does ertapenem affect <i>Pseudomonas</i> susceptibility to other carbapenems? A review of the evidence	Nicolau DP, Carmeli Y , Crank CW, Goff DA, Graber CJ, Lima AL, Goldstein EJ.	Int J Antimicrob Agents. 2012 Jan;39(1):11-5.
Molecular epidemiology of methicillin-resistant <i>Staphylococcus aureus</i> in Israel: dissemination of global clones and unique features	Adler A, Chmelnitsky I, Shitrit P, Sprecher H, Navon-Venezia S, Embon A, Khabra E, Paitan Y, Keren L, Halperin E, Carmeli Y , Schwaber MJ.	J Clin Microbiol. 2012 Jan;50(1):134-7.
<i>Pseudomonas aeruginosa</i> bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy	Schechner V, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, Karplus R, Lazarovitch T, Braun E, Finkelstein R, Lachish T, Wiener-Well Y, Alon D, Chowers M, Bardenstein R, Zimhony O, Paz A, Potasman I, Giladi M, Schwaber MJ, Klarfeld-Lidji S, Hochman M, Marchaim D, Carmeli Y .	Diagn Microbiol Infect Dis. 2011 Sep;71(1):38-45.
High prevalence of methicillin-resistant <i>Staphylococcus aureus</i> among residents and staff of long-term care facilities, involving joint and parallel evolution	Schwaber MJ, Masarwa S, Navon-Venezia S, Kandlik Y, Chmelnitsky I, Smollan G, Glick R, Neria G, Carmeli Y .	Clin Infect Dis. 2011 Nov;53(9):910-3.
Carbapenem-resistant <i>Klebsiella pneumoniae</i> in post-acute-care facilities in Israel	Ben-David D, Masarwa S, Navon-Venezia S, Mishali H, Fridental I, Rubinovitch B, Smollan G, Carmeli Y , Schwaber MJ; Israel PACF CRKP (Post-Acute-Care Facility Carbapenem-Resistant <i>Klebsiella pneumoniae</i>) Working Group.	Infect Control Hosp Epidemiol. 2011 Sep;32(9):845-53.
Dissemination of an NDM-2-producing <i>Acinetobacter baumannii</i> clone in an Israeli rehabilitation center	Espinal P, Fugazza G, López Y, Kasma M, Lerman Y, Malhotra-Kumar S, Goossens H, Carmeli Y , Vila J.	Antimicrob Agents Chemother. 2011 Nov;55(11):5396-8.
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance	Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y , Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL	Clin Microbiol Infect. 2012 Mar;18(3):268-81.
Laboratory evaluation of the CHROMagar KPC medium for identification of carbapenem-nonsusceptible Enterobacteriaceae	Moran Gilad J, Carmeli Y , Schwartz D, Navon-Venezia S.	Diagn Microbiol Infect Dis. 2011 Aug;70(4):565-7.

The effects of group 1 versus group 2 carbapenems on imipenem-resistant <i>Pseudomonas aeruginosa</i> : an ecological study	Carmeli Y , Lidji SK, Shabtai E, Navon-Venezia S, Schwaber MJ.	Diagn Microbiol Infect Dis. 2011 Jul;70(3):367-72.
Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region	Hsueh PR, Hoban DJ, Carmeli Y , Chen SY, Desikan S, Alejandria M, Ko WC, Binh TQ.	J Infect. 2011 Aug;63(2):114-23.
A call for action: the application of The International Health Regulations to the global threat of antimicrobial resistance	Wernli D, Hausteiner T, Conly J, Carmeli Y , Kickbusch I, Harbarth S.	PLoS Med. 2011 Apr;8(4):e1001022.
Predictors of rectal carriage of carbapenem-resistant Enterobacteriaceae (CRE) among patients with known CRE carriage at their next hospital encounter	Schechner V, Kotlovsky T, Tarabeia J, Kazma M, Schwartz D, Navon-Venezia S, Carmeli Y .	Infect Control Hosp Epidemiol. 2011 May;32(5):497-503
Laboratory and clinical evaluation of screening agar plates for detection of carbapenem-resistant Enterobacteriaceae from surveillance rectal swabs	Adler A, Navon-Venezia S, Moran-Gilad J, Marcos E, Schwartz D, Carmeli Y .	J Clin Microbiol. 2011 Jun;49(6):2239-42.
Containment of a country-wide outbreak of carbapenem-resistant <i>Klebsiella pneumoniae</i> in Israeli hospitals via a nationally implemented intervention	Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, Shalit I, Carmeli Y ; Israel Carbapenem-Resistant Enterobacteriaceae Working Group.	Clin Infect Dis. 2011 Apr 1;52(7):848-55.
Fighting bacterial resistance at the root: need for adapted EMEA guidelines	Andremont A, Bonten M, Kluytmans J, Carmeli Y , Cars O, Harbarth S.	Lancet Infect Dis. 2011 Jan;11(1):6-8.
Plasmid-encoded OXA-48 carbapenemase in <i>Escherichia coli</i> from Israel	Goren MG, Chmelnitsky I, Carmeli Y , Navon-Venezia S.	J Antimicrob Chemother. 2011 Mar;66(3):672-3.
Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts	Grundmann H, Livermore DM, Giske CG, Canton R, Rossolini GM, Campos J, Vatopoulos A, Gniadkowski M, Toth A, Pfeifer Y, Jarlier V, Carmeli Y ; CNSE Working Group.	Euro Surveill. 2010 Nov 18;15(46). pii: 19711. Erratum in: Euro Surveill. 2011;16(3). pii: 19766.
Predictors of pandemic (H1N1) 2009 virus positivity and adverse outcomes among hospitalized patients with a compatible syndrome	Shlomai A, Nutman A, Kotlovsky T, Schechner V, Carmeli Y , Guzman-Gur H.	Isr Med Assoc J. 2010 Oct;12(10):622-7.
Antimicrobial susceptibility of intra-abdominal gram-negative bacilli from Europe: SMART Europe 2008	Hawser S, Hoban D, Bouchillon S, Badal R, Carmeli Y , Hawkey P.	Eur J Clin Microbiol Infect Dis. 2011 Feb;30(2):173-9
National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases	Marchaim D, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, Karplus R, Lazarovitch T, Braun E, Sprecher H, Lachish T, Wiener-Well Y, Alon D, Chowers M, Ciobotaro P, Bardenstein R, Paz A,	Antimicrob Agents Chemother. 2010 Dec;54(12):5099-104

	Potzman I, Giladi M, Schechner V, Schwaber MJ, Klarfeld-Lidji S, Carmeli Y.	
Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene	Cuzon G, Naas T, Truong H, Villegas MV, Wisell KT, Carmeli Y , Gales AC, Venezia SN, Quinn JP, Nordmann P.	Emerg Infect Dis. 2010 Sep;16(9):1349-56.
Complete nucleotide sequence of KPC-3-encoding plasmid pKpQIL in the epidemic Klebsiella pneumoniae sequence type 258	Leavitt A, Chmelnitsky I, Carmeli Y , Navon-Venezia S.	Antimicrob Agents Chemother. 2010 Oct;54(10):4493-6.
How to stem the tide of carbapenemase-producing enterobacteriaceae?: proactive versus reactive strategies	Bilavsky E, Schwaber MJ, Carmeli Y.	Curr Opin Infect Dis. 2010 Aug;23(4):327-31.
Transfer of carbapenem-resistant plasmid from Klebsiella pneumoniae ST258 to Escherichia coli in patient	Goren MG, Carmeli Y , Schwaber MJ, Chmelnitsky I, Schechner V, Navon-Venezia S.	Emerg Infect Dis. 2010 Jun;16(6):1014-7.
The pivotal role of long-term care facilities in the epidemiology of Acinetobacter baumannii: another brick in the wall	de Medina T, Carmeli Y.	Clin Infect Dis. 2010 Jun 15;50(12):1617-8.
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel	Leavitt A, Carmeli Y , Chmelnitsky I, Goren MG, Ofek I, Navon-Venezia S.	Antimicrob Agents Chemother. 2010 Jul;54(7):3002-6.
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008	Goren MG, Navon-Venezia S, Chmelnitsky I, Carmeli Y.	Antimicrob Agents Chemother. 2010 Jun;54(6):2687-91.
Intercontinental spread from Israel to Colombia of a KPC-3-producing Klebsiella pneumoniae strain	Lopez JA, Correa A, Navon-Venezia S, Correa AL, Torres JA, Briceño DF, Montealegre MC, Quinn JP, Carmeli Y , Villegas MV.	Clin Microbiol Infect. 2011 Jan;17(1):52-6.
Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients	Wener KM, Schechner V, Gold HS, Wright SB, Carmeli Y.	Antimicrob Agents Chemother. 2010 May;54(5):2010-6.
Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control	Carmeli Y , Akova M, Cornaglia G, Daikos GL, Garau J, Harbarth S, Rossolini GM, Souli M, Giamarellou H.	Clin Microbiol Infect. 2010 Feb;16(2):102-11.
Plasmid pKpQIL encoding KPC-3 and TEM-1 confers carbapenem resistance in an extremely drug-resistant epidemic Klebsiella pneumoniae strain	Leavitt A, Chmelnitsky I, Ofek I, Carmeli Y , Navon-Venezia S.	J Antimicrob Chemother. 2010 Feb;65(2):243-8.